½ÃÀ庸°í¼­
»óǰÄÚµå
1399615

¸» ÇコÄÉ¾î ½ÃÀå ±Ô¸ð : Á¦Ç°º°, ÀûÀÀÁõº°, À¯Åë ä³Îº° - ¼¼°è ¿¹Ãø(2023-2032³â)

Equine Healthcare Market Size - By Product (Vaccines, Pharmaceuticals, Medical Additives, Diagnostics), Indication (Parasite Control, Equine Encephalomyelitis, Equine Influenza), Distribution Channel, Global Forecast, 2023-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 160 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¸» ÇコÄÉ¾î ½ÃÀå ±Ô¸ð´Â ¸» ¿¹¹æ ÀÇ·á ´ëÃ¥ÀÇ Áß½ÃÀÇ Áõ°¡¿¡ ÀÇÇØ 2023-2032³â CAGR 6.4%·Î È®´ëÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÃÖ±Ù ¼ö³â°£ ¸¶ÁÖ¿Í ¼öÀÇ»çµéÀº ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥, ±â»ýÃæ ±¸Á¦, Á¤±â °ËÁø µî ¿¹¹æÀû ÇコÄɾîÀÇ Á߿伺À» ÀνÄÇϰí ÀÖ½À´Ï´Ù. ¿¹¹æ Á¶Ä¡´Â ¸»ÀÇ Àü¹ÝÀûÀÎ °Ç°­À» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó ¼º´ÉÀ» ÃÖÀûÈ­ÇÏ°í ¼ö¸íÀ» ¿¬ÀåÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¿¹¹æ ÀÇ·á·ÎÀÇ ÀüȯÀº ¸»ÀÇ ÇコÄɾî¿Í Ȱ·Â À¯Áö¿¡ ´ëÇÑ ³ë·ÂÀ» ¹Ý¿µÇϰí ÀÖÀ¸¸ç, ¿¹¹æ °ü¸® Á¦Ç° ¹× ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ ÀϺΠ½ÃÀå ÁøÃâ±â¾÷Àº ¸»ÀÇ ´Ù¾çÇÑ °Ç°­ ¿ä±¸¸¦ ÃæÁ·½Ã۱â À§ÇØ »õ·Î¿î Á¦Ç°°ú ¼­ºñ½º¸¦ Ãâ½ÃÇϱâ À§ÇØ ´ë±Ô¸ð R&D ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 4¿ù Hilltop Bio´Â Çõ½ÅÀûÀÎ ¸» °üÀý °Ç°­ ¼Ö·ç¼ÇÀÎ Strydaflex¸¦ Ãâ½ÃÇÏ¿© »ó¿Â Àç»ý ÀǾàǰÀÇ ¹üÀ§¸¦ È®´ëÇß½À´Ï´Ù.

¸» ÇコÄÉ¾î »ê¾÷Àº Á¦Ç°, ÀûÀÀÁõ, À¯Åë ä³Î, Áö¿ªÀ¸·Î ±¸ºÐµË´Ï´Ù.

Á¦Ç°º°·Î´Â ¹é½Å ºÐ¾ß ½ÃÀå Á¡À¯À²ÀÌ 2023-2032³â 7.2%ÀÇ CAGRÀ» ±â·ÏÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ¹é½ÅÀº ¸»ÀÇ Àü¿°º´À» ¿¹¹æÇÏ°í °ü¸®Çϱâ À§ÇØ ¸¹Àº °ü½ÉÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇöÀç ÁøÇàÁßÀÎ ¿¬±¸°³¹ß ³ë·ÂÀº Á¾ÇÕÀû ÀÎ º¸È£¸¦ º¸ÀåÇϱâ À§ÇØ °í±Þ ¹× Ư¼ö ¸» ¹é½ÅÀ» ¸¸µå´Â µ¥ ±â¿©ÇÏ¿© Á¦Ç° ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

À¯Åë ä³Î Ãø¸é¿¡¼­ E-Commerce ºÎ¹®ÀÇ ¸» °Ç°­°ü¸® ½ÃÀåÀº 2022³â¿¡ »ó´çÇÑ ¸ÅÃâÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2032³â CAGRÀº 7%¸¦ º¸ÀÏ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¿Â¶óÀÎ Ç÷§ÆûÀº ´Ù¾çÇÑ ¸» °Ç°­ Á¦Ç°, º¸ÃæÁ¦ ¹× ÀǾàǰ¿¡ ´ëÇÑ Á¢±ÙÀ» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ E-Commerce »çÀÌÆ®´Â ¸» ¼ÒÀ¯ÀÚ¿Í ¼öÀÇ»ç Àü¹®°¡°¡ ÁýÀ̳ª Ŭ¸®´Ð¿¡¼­ Æí¾ÈÇÏ°Ô Á¦Ç°À» °Ë»ö, ºñ±³ ¹× ±¸¸ÅÇÒ ¼ö ÀÖ´Â Æí¸®ÇÔÀ» Á¦°øÇÏ¿© ÀÌ ºÎ¹®ÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Áö¿ªº°·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸» ÇコÄÉ¾î »ê¾÷Àº ¸¶¼ú ¹®È­ÀÇ Àαâ Áõ°¡¿Í ÀÌ Áö¿ª¿¡¼­ °í¼º´É¸»ÀÇ ¼ö¿ä Áõ°¡¿¡ ÀÇÇØ Áö¿øµÇ¸ç, 2023-2032³â 7%ÀÇ ¼ºÀå·ü·Î °ß°íÇÑ ¼ºÀåÀ» ³ªÅ¸³¾ °ÍÀ¸·Î º¸À̰í ÀÖ½À´Ï´Ù. ¸¶¼ú ½Ã¼³ °³¹ßÀ» À§ÇÑ Á¤ºÎ ¹× ¹Î°£ ºÎ¹®ÀÇ ÅõÀÚ°¡ ±ÞÁõÇϸç, ¸» ÇコÄɾ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾Æ½Ã¾ÆÀÇ ÁÖ¿ä ±¹°¡¿¡¼­´Â ·¹À̽º, ½ºÆ÷Ã÷, ·¹Àú µî ´Ù¾çÇÑ ¸¶¼ú Ȱµ¿ÀÌ Àα⸦ ²ø°í ÀÖÀ¸¸ç, ÀÌ Áö¿ªÀÇ ½ÃÀå È®´ë¸¦ ÇÑÃþ ´õ °¡¼Ó½Ãų °ÍÀ¸·Î »ý°¢µË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¸¶ ÇコÄÉ¾î ½ÃÀå ÀλçÀÌÆ®

  • ¾÷°è »óȲ
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • ¸¶¼ú ½ºÆ÷Ã÷ÀÇ ¼ºÀå
      • µ¿¹° ÀÇ·áºñÀÇ Áõ°¡
      • Á¤ºÎ ¹× °øÀû ±â°ü¿¡ ÀÇÇÑ µ¿¹° Äɾ ´ëÇÑ Áö¿øÀÇ Áõ°¡
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©¡¤°úÁ¦
      • ¼÷·Ã ¼öÀÇ»çÀÇ ºÎÁ·
  • ¼ºÀåÀÇ °¡´É¼º ºÐ¼®
  • COVID-19 ¿µÇ⠺м®
  • ±ÔÁ¦ »óȲ
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ¸¶ ÇコÄÉ¾î ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Á¦Ç°º°

  • ÁÖ¿ä µ¿Çâ : Á¦Ç°º°
  • ¹é½Å
  • ÀǾàǰ
    • ±¸ÃæÁ¦
    • Ç×°¨¿°Á¦
    • ¼Ò¿° ÁøÅëÁ¦
    • ±âŸ ÀǾàǰ
  • »ç·á÷°¡Á¦
  • Áø´Ü¾à
  • ±âŸ Á¦Ç°

Á¦6Àå ¸¶ ÇコÄÉ¾î ½ÃÀå ÃßÁ¤¡¤¿¹Ãø, ÀûÀÀÁõº°

  • ÁÖ¿ä µ¿Çâ : ÀûÀÀÁõº°
  • ±Ù°ñ°Ý°è Áúȯ
  • ±â»ýÃæ ¹æÁ¦
  • ¸» Ç츣Æä½º
  • ¸» ³úô¼ö¿°
  • ¸» ÀÎÇ÷翣ÀÚ
  • ÆÄ»ódz
  • ¿þ½ºÆ® ³ªÀÏ ¹ÙÀÌ·¯½º
  • ±âŸ ÀûÀÀÁõ

Á¦7Àå ¸¶ ÇコÄÉ¾î ½ÃÀå ÃßÁ¤¡¤¿¹Ãø, À¯Åë ä³Îº°

  • ÁÖ¿ä µ¿Çâ : À¯Åë ä³Îº°
  • µ¿¹°º´¿ø ¾à±¹
  • E-Commerce
  • ±âŸ À¯Åë ä³Î

Á¦8Àå ¸¶ ÇコÄÉ¾î ½ÃÀå ÃßÁ¤¡¤¿¹Ãø, Áö¿ªº°

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ±â¾÷ °³¿ä

  • Zoetis
  • Boehringer Ingelheim International GmbH
  • MERCK & CO., INC.
  • Vetoquinol S.A.
  • Ceva
  • Hallmarq Veterinary Imaging
  • SOUND
  • ESAOTE SPA
  • Dechra Pharmaceuticals PLC
  • IDEXX Laboratories, Inc.
  • Sante Animale
KSA 24.01.04

Equine Healthcare Market size is anticipated to expand at 6.4% CAGR from 2023-2032 driven by the growing emphasis on preventive healthcare measures for horses. Of late, horse owners and veterinarians are increasingly recognizing the importance of proactive health management, including vaccination programs, parasite control, and routine check-ups. Preventive measures not only enhance the overall well-being of horses but also boost performance optimization and longevity. The shift towards preventive healthcare approaches also reflects a commitment to maintaining the health and vitality of equine populations, driving the demand for preventive care products and services.

Furthermore, several industry participants are making massive R&D investments to launch new products and services for catering to different health needs of horses, in turn, supporting the market growth. For instance, in April 2023, Hilltop Bio expanded its range of room-temperature regenerative medicines with the launch of Strydaflex, an innovative horse joint health solution.

The equine healthcare industry is segmented into product, indication, distribution channel, and region.

Based on product, the market share from the vaccines segment is likely to witness 7.2% CAGR from 2023-2032 attributed to the rising emphasis on animal health and welfare in the global equine domain. Vaccines are gaining prominence for preventing and controlling numerous infectious diseases among horses. Additionally, the ongoing R&D efforts are contributing to the creation of advanced and specialized equine vaccines for ensuring comprehensive protection, boosting the product demand.

In terms of distribution channel, the equine healthcare market from the e-commerce segment recorded substantial sales in 2022 and is estimated to depict 7% CAGR from 2023 to 2032. Online platforms facilitate easy access to a wide range of equine health products, supplements, and medications. Additionally, e-commerce sites offer convenience for enabling horse owners and veterinary professionals to browse, compare, and purchase products from the comfort of their homes and clinics, thereby contributing to the segment growth.

Regionally, the Asia Pacific equine healthcare industry is set to exhibit robust growth at a 7% growth rate between 2023 and 2032 propelled by the rising popularity of equestrian culture, and the growing demand for high-performance horses in the region. Surging government and private sector investments for the development of equine facilities has led to the higher awareness about horse health. Moreover, the popularity of diverse equine activities, including racing, sports, and leisure across the major Asian countries will further accelerate the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market definition
  • 1.2 Base estimates & calculations
  • 1.3 Forecast Calculation
  • 1.4 COVID-19 impact analysis at global level
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Equine healthcare industry 360 degree synopsis, 2018 - 2032 (USD Million)
    • 2.1.1 Business trends
    • 2.1.2 Regional trends
    • 2.1.3 Product trends
    • 2.1.4 Indication trends
    • 2.1.5 Distribution channel trends

Chapter 3 Equine healthcare market Insights

  • 3.1 Industry landscape, 2018 - 2032 (USD Million)
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing equestrian sports
      • 3.2.1.2 Rise in animal health expenditure
      • 3.2.1.3 Increasing support offered by government and public organizations for animal care.
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Shortage of skilled veterinarians
  • 3.3 Growth potential analysis
    • 3.3.1 By product
    • 3.3.2 By indication
    • 3.3.3 By distribution channel
  • 3.4 COVID-19 impact analysis
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Competitive analysis of major market players, 2022
  • 4.4 Competitive positioning matrix, 2022
  • 4.5 Strategic dashboard, 2022

Chapter 5 Equine Healthcare Market Estimates and Forecast, By Product, 2018-2032 (USD Million)

  • 5.1 Key trends, by product
  • 5.2 Vaccines
  • 5.3 Pharmaceuticals
    • 5.3.1 Parasiticides
    • 5.3.2 Anti-Infective
    • 5.3.3 Anti-Inflammatory & Analgesics
    • 5.3.4 Other pharmaceuticals
  • 5.4 Medicinal Feed Additives
  • 5.5 Diagnostics
  • 5.6 Other products

Chapter 6 Equine Healthcare Market Estimates and Forecast, By Indication, 2018-2032 (USD Million)

  • 6.1 Key trends, by indication
  • 6.2 Musculoskeletal disorders
  • 6.3 Parasite control
  • 6.4 Equine herpes
  • 6.5 Equine encephalomyelitis
  • 6.6 Equine influenza
  • 6.7 Tetanus
  • 6.8 West Nile Virus
  • 6.9 Other indications

Chapter 7 Equine Healthcare Market Estimates and Forecast, By Distribution Channel, 2018-2032 (USD Million)

  • 7.1 Key trends, by distribution channel
  • 7.2 Veterinary hospital pharmacies
  • 7.3 E-commerce
  • 7.4 Other distribution channels

Chapter 8 Equine Healthcare Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

  • 8.1 Key trends, by region
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest of Latin America
  • 8.6 Middle East & Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 Rest of Middle East & Africa

Chapter 9 Company Profiles

  • 9.1 Zoetis
  • 9.2 Boehringer Ingelheim International GmbH
  • 9.3 MERCK & CO., INC.
  • 9.4 Vetoquinol S.A.
  • 9.5 Ceva
  • 9.6 Hallmarq Veterinary Imaging
  • 9.7 SOUND
  • 9.8 ESAOTE SPA
  • 9.9 Dechra Pharmaceuticals PLC
  • 9.10 IDEXX Laboratories, Inc.
  • 9.11 Sante Animale
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦